Question 1201 — pharmacy and medications

Summary

Mr. Paul Christophe draws the attention of the Minister of Solidarity and Health to the drug treatment of myeloma. Myeloma is a rare disease of the blood-forming marrow. It affects nearly 5,000 new people each year. According to estimates, 30,000 people in France are affected today. Although modern treatments have significantly increased the average survival time, myeloma remains a particularly fatal disease. Survival is estimated at 24 to 48 months depending on the prognosis. However, clinical research undertaken over the last decade has given rise to real hope of remission for patients. In 2015, the European Medicines Agency issued marketing authorizations for five new medicines (panobinostat, ixazomib, carfilzomib, daratumumab and elotuzumab). These medications innovative solutions are already used to treat patients in Germany and Spain. In France, marketing authorizations have not yet been issued. Patients do not understand this administrative blockage when it is a question of their survival. Therefore, he would like to know whether the ministry intends to take the necessary measures so that these innovative medicines can be made available to patients.

Machine translation from French. The official text remains authoritative.

Timeline

No timeline events have been ingested for this record yet.

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

No documents linked.

Sponsors

No sponsors or actors listed by the source.

Related records

No cross-record relationships stored yet.